Shares in Chinese drug developer Jacobio Pharmaceuticals Group Co. Ltd. (HK:1167) rose 3% on their first day of trading in Hong Kong. The company, which develops small-molecule drug candidates to modulate enzymes by binding to their allosteric sites, raised HK$1.35 billion (US$174.1 million) in its IPO, pricing 96 million shares at HK$14. Shares closed at HK$14.42 on Dec. 21 after rising as high as HK$16.50.
Biopharmas raising money in public or private financings, including: AB Science, Bioatla, Healthcare Capital, Hemostemix, Locust Walk, Qualigen, Scopus.
DUBLIN – Minervax Aps raised €47.4 million (US$57.6 million) in a series B funding round to take a recombinant-protein-based vaccine for group B streptococcus (GBS) through a phase II program as well as parallel surveillance studies to enable it to define correlates of protection against GBS in newly born infants.
RSS
